

ClÃ©mence Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9281365/publications.pdf>

Version: 2024-02-01

27
papers

731
citations

686830

13
h-index

552369

26
g-index

28
all docs

28
docs citations

28
times ranked

809
citing authors

#	ARTICLE	IF	CITATIONS
1	Cystic Fibrosis in 2021: "The Times They Are A-Changin", Archivos De Bronconeumologia, 2022, 58, 536-538.	0.4	1
2	Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 489-496.	0.3	38
3	Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 584-586.	2.5	26
4	Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021. Respiratory Medicine and Research, 2022, 81, 100889.	0.4	0
5	CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells, 2022, 11, 1769.	1.8	17
6	Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test. European Respiratory Journal, 2022, 60, 2200209.	3.1	8
7	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis, 2021, 20, 220-227.	0.3	24
8	Effective control of <i>Staphylococcus aureus</i> lung infection despite tertiary lymphoid structure disorganisation. European Respiratory Journal, 2021, 57, 2000768.	3.1	6
9	Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 64-73.	2.5	139
10	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653.	3.1	16
11	Reply to Kuek et al.: Optimism with Caution: Elexacaftor-Tezacaftor-Ivacaftor in Patients with Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 372-374.	2.5	10
12	Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries. European Respiratory Journal, 2021, 58, 2101487.	3.1	2
13	Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report. Allergy, Asthma and Immunology Research, 2021, 13, 515.	1.1	7
14	Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis. European Respiratory Journal, 2021, , 2101344.	3.1	19
15	Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 188-197.	2.5	95
16	Impact of panelists' experience on script concordance test scores of medical students. BMC Medical Education, 2020, 20, 313.	1.0	15
17	Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?. European Respiratory Journal, 2020, 56, 2002645.	3.1	5
18	Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores. Radiology: Cardiothoracic Imaging, 2020, 2, e200022.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Do Cough and Sputum Production Predict COPD Exacerbations?. Chest, 2019, 156, 641-642.	0.4	6
20	Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 592-602.	2.5	40
21	Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis. Journal of Clinical Pathology, 2018, 71, 752-753.	1.0	4
22	Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs. Methods in Molecular Biology, 2018, 1845, 223-239.	0.4	10
23	Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. European Respiratory Journal, 2017, 49, 1601873.	3.1	38
24	Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infection and Drug Resistance, 2016, Volume 9, 229-238.	1.1	53
25	Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!. Journal of Cystic Fibrosis, 2016, 15, 204-212.	0.3	76
26	Prognostic value of six minute walk test in cystic fibrosis adults. Respiratory Medicine, 2013, 107, 1881-1887.	1.3	51
27	Dysfunctional lung anatomy and small airways degeneration in COPD. International Journal of COPD, 2013, 8, 7.	0.9	17